A review of current and promising nontuberculous mycobacteria antibiotics
Nontuberculous mycobacteria infections are a growing concern, and their incidence has been increasing worldwide in recent years. Current treatments are not necessarily useful because many were initially designed to work against other bacteria, such as . In addition, inadequate treatment means that r...
Gespeichert in:
| Veröffentlicht in: | Future medicinal chemistry 2021-08, Vol.13 (16), p.1367-1395 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1395 |
|---|---|
| container_issue | 16 |
| container_start_page | 1367 |
| container_title | Future medicinal chemistry |
| container_volume | 13 |
| creator | Cantelli, Christophe R. Dassonville-Klimpt, Alexandra Sonnet, Pascal |
| description | Nontuberculous mycobacteria infections are a growing concern, and their incidence has been increasing worldwide in recent years. Current treatments are not necessarily useful because many were initially designed to work against other bacteria, such as
. In addition, inadequate treatment means that resistant strains are increasingly appearing, particularly for
, one of the most virulent nontuberculous mycobacteria. There is an urgent need to develop new antibiotics specifically directed against these nontuberculous mycobacteria. To help in this fight against the emergence of these pathogens, this review describes the most promising heterocyclic antibiotics under development, with particular attention paid to their structure–activity relationships. |
| doi_str_mv | 10.4155/fmc-2021-0048 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03611918v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2544879470</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-be8f9f22b0ee76add687ac4b6bed261fdba9c55bd28d66f72c4cd36d58f3e3323</originalsourceid><addsrcrecordid>eNqNkctrFTEUxgdRbKldupVZKjI1j8ljlpdLtYUL3eg65HGikblJTTIt_e_NMO3dCWZzksPvfOT7Tte9x-hqxIx98Uc7EETwgNAoX3XnWDA-yImI16c7ns66y1J-o3YokRNnb7szOmLOKGHn3e2uz_AQ4LFPvrdLzhBrr6Pr73M6hhLizz6mWBcD2S5zWkp_fLLJaFshB93IGkxINdjyrnvj9Vzg8rledD--Xn_f3wyHu2-3-91hsFSIOhiQfvKEGAQguHaOS6HtaLgBRzj2zujJMmYckY5zL4gdraPcMekpUEroRfdp0_2lZ3Wfw1HnJ5V0UDe7g1p7iHKMJywfcGM_bmxz82eBUlXzZGGedYTmRRE2jlJMo0ANHTbU5lRKBn_SxkitYasWtlrDVmvYjf_wLL2YI7gT_RJtA-QGPIJJvtgA0cIJa9vgXEhC1r0gvA9V15DiPi2xttHP_z_a6Gmj_VKXDC_49mpfCzZE-IeLv4lDrzg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2544879470</pqid></control><display><type>article</type><title>A review of current and promising nontuberculous mycobacteria antibiotics</title><source>MEDLINE</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>PubMed Central</source><creator>Cantelli, Christophe R. ; Dassonville-Klimpt, Alexandra ; Sonnet, Pascal</creator><creatorcontrib>Cantelli, Christophe R. ; Dassonville-Klimpt, Alexandra ; Sonnet, Pascal</creatorcontrib><description>Nontuberculous mycobacteria infections are a growing concern, and their incidence has been increasing worldwide in recent years. Current treatments are not necessarily useful because many were initially designed to work against other bacteria, such as
. In addition, inadequate treatment means that resistant strains are increasingly appearing, particularly for
, one of the most virulent nontuberculous mycobacteria. There is an urgent need to develop new antibiotics specifically directed against these nontuberculous mycobacteria. To help in this fight against the emergence of these pathogens, this review describes the most promising heterocyclic antibiotics under development, with particular attention paid to their structure–activity relationships.</description><identifier>ISSN: 1756-8919</identifier><identifier>EISSN: 1756-8927</identifier><identifier>DOI: 10.4155/fmc-2021-0048</identifier><identifier>PMID: 34165325</identifier><language>eng</language><publisher>London: Newlands Press Ltd</publisher><subject>Anti-Bacterial Agents - chemistry ; Anti-Bacterial Agents - pharmacology ; antibiotics ; atypical mycobacteria ; Chemical Sciences ; Chemistry, Medicinal ; Heterocyclic Compounds - chemistry ; Heterocyclic Compounds - pharmacology ; heterocylic compounds ; Life Sciences ; Life Sciences & Biomedicine ; mechanisms of action ; Microbial Sensitivity Tests ; Molecular Structure ; Mycobacterium Infections, Nontuberculous - drug therapy ; Mycobacterium Infections, Nontuberculous - microbiology ; nontuberculous mycobacteria ; Nontuberculous Mycobacteria - drug effects ; Pharmacology & Pharmacy ; Science & Technology ; Structure-Activity Relationship ; structure–activity relationships</subject><ispartof>Future medicinal chemistry, 2021-08, Vol.13 (16), p.1367-1395</ispartof><rights>2021 Newlands Press</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>7</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000667822000001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c377t-be8f9f22b0ee76add687ac4b6bed261fdba9c55bd28d66f72c4cd36d58f3e3323</citedby><cites>FETCH-LOGICAL-c377t-be8f9f22b0ee76add687ac4b6bed261fdba9c55bd28d66f72c4cd36d58f3e3323</cites><orcidid>0000-0003-0118-9151 ; 0000-0002-2891-9102</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,781,785,886,27929,27930,39263</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34165325$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://u-picardie.hal.science/hal-03611918$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Cantelli, Christophe R.</creatorcontrib><creatorcontrib>Dassonville-Klimpt, Alexandra</creatorcontrib><creatorcontrib>Sonnet, Pascal</creatorcontrib><title>A review of current and promising nontuberculous mycobacteria antibiotics</title><title>Future medicinal chemistry</title><addtitle>FUTURE MED CHEM</addtitle><addtitle>Future Med Chem</addtitle><description>Nontuberculous mycobacteria infections are a growing concern, and their incidence has been increasing worldwide in recent years. Current treatments are not necessarily useful because many were initially designed to work against other bacteria, such as
. In addition, inadequate treatment means that resistant strains are increasingly appearing, particularly for
, one of the most virulent nontuberculous mycobacteria. There is an urgent need to develop new antibiotics specifically directed against these nontuberculous mycobacteria. To help in this fight against the emergence of these pathogens, this review describes the most promising heterocyclic antibiotics under development, with particular attention paid to their structure–activity relationships.</description><subject>Anti-Bacterial Agents - chemistry</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>antibiotics</subject><subject>atypical mycobacteria</subject><subject>Chemical Sciences</subject><subject>Chemistry, Medicinal</subject><subject>Heterocyclic Compounds - chemistry</subject><subject>Heterocyclic Compounds - pharmacology</subject><subject>heterocylic compounds</subject><subject>Life Sciences</subject><subject>Life Sciences & Biomedicine</subject><subject>mechanisms of action</subject><subject>Microbial Sensitivity Tests</subject><subject>Molecular Structure</subject><subject>Mycobacterium Infections, Nontuberculous - drug therapy</subject><subject>Mycobacterium Infections, Nontuberculous - microbiology</subject><subject>nontuberculous mycobacteria</subject><subject>Nontuberculous Mycobacteria - drug effects</subject><subject>Pharmacology & Pharmacy</subject><subject>Science & Technology</subject><subject>Structure-Activity Relationship</subject><subject>structure–activity relationships</subject><issn>1756-8919</issn><issn>1756-8927</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>EIF</sourceid><recordid>eNqNkctrFTEUxgdRbKldupVZKjI1j8ljlpdLtYUL3eg65HGikblJTTIt_e_NMO3dCWZzksPvfOT7Tte9x-hqxIx98Uc7EETwgNAoX3XnWDA-yImI16c7ns66y1J-o3YokRNnb7szOmLOKGHn3e2uz_AQ4LFPvrdLzhBrr6Pr73M6hhLizz6mWBcD2S5zWkp_fLLJaFshB93IGkxINdjyrnvj9Vzg8rledD--Xn_f3wyHu2-3-91hsFSIOhiQfvKEGAQguHaOS6HtaLgBRzj2zujJMmYckY5zL4gdraPcMekpUEroRfdp0_2lZ3Wfw1HnJ5V0UDe7g1p7iHKMJywfcGM_bmxz82eBUlXzZGGedYTmRRE2jlJMo0ANHTbU5lRKBn_SxkitYasWtlrDVmvYjf_wLL2YI7gT_RJtA-QGPIJJvtgA0cIJa9vgXEhC1r0gvA9V15DiPi2xttHP_z_a6Gmj_VKXDC_49mpfCzZE-IeLv4lDrzg</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Cantelli, Christophe R.</creator><creator>Dassonville-Klimpt, Alexandra</creator><creator>Sonnet, Pascal</creator><general>Newlands Press Ltd</general><general>Future Science</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-0118-9151</orcidid><orcidid>https://orcid.org/0000-0002-2891-9102</orcidid></search><sort><creationdate>20210801</creationdate><title>A review of current and promising nontuberculous mycobacteria antibiotics</title><author>Cantelli, Christophe R. ; Dassonville-Klimpt, Alexandra ; Sonnet, Pascal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-be8f9f22b0ee76add687ac4b6bed261fdba9c55bd28d66f72c4cd36d58f3e3323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Anti-Bacterial Agents - chemistry</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>antibiotics</topic><topic>atypical mycobacteria</topic><topic>Chemical Sciences</topic><topic>Chemistry, Medicinal</topic><topic>Heterocyclic Compounds - chemistry</topic><topic>Heterocyclic Compounds - pharmacology</topic><topic>heterocylic compounds</topic><topic>Life Sciences</topic><topic>Life Sciences & Biomedicine</topic><topic>mechanisms of action</topic><topic>Microbial Sensitivity Tests</topic><topic>Molecular Structure</topic><topic>Mycobacterium Infections, Nontuberculous - drug therapy</topic><topic>Mycobacterium Infections, Nontuberculous - microbiology</topic><topic>nontuberculous mycobacteria</topic><topic>Nontuberculous Mycobacteria - drug effects</topic><topic>Pharmacology & Pharmacy</topic><topic>Science & Technology</topic><topic>Structure-Activity Relationship</topic><topic>structure–activity relationships</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cantelli, Christophe R.</creatorcontrib><creatorcontrib>Dassonville-Klimpt, Alexandra</creatorcontrib><creatorcontrib>Sonnet, Pascal</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Future medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cantelli, Christophe R.</au><au>Dassonville-Klimpt, Alexandra</au><au>Sonnet, Pascal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A review of current and promising nontuberculous mycobacteria antibiotics</atitle><jtitle>Future medicinal chemistry</jtitle><stitle>FUTURE MED CHEM</stitle><addtitle>Future Med Chem</addtitle><date>2021-08-01</date><risdate>2021</risdate><volume>13</volume><issue>16</issue><spage>1367</spage><epage>1395</epage><pages>1367-1395</pages><issn>1756-8919</issn><eissn>1756-8927</eissn><abstract>Nontuberculous mycobacteria infections are a growing concern, and their incidence has been increasing worldwide in recent years. Current treatments are not necessarily useful because many were initially designed to work against other bacteria, such as
. In addition, inadequate treatment means that resistant strains are increasingly appearing, particularly for
, one of the most virulent nontuberculous mycobacteria. There is an urgent need to develop new antibiotics specifically directed against these nontuberculous mycobacteria. To help in this fight against the emergence of these pathogens, this review describes the most promising heterocyclic antibiotics under development, with particular attention paid to their structure–activity relationships.</abstract><cop>London</cop><pub>Newlands Press Ltd</pub><pmid>34165325</pmid><doi>10.4155/fmc-2021-0048</doi><tpages>29</tpages><orcidid>https://orcid.org/0000-0003-0118-9151</orcidid><orcidid>https://orcid.org/0000-0002-2891-9102</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1756-8919 |
| ispartof | Future medicinal chemistry, 2021-08, Vol.13 (16), p.1367-1395 |
| issn | 1756-8919 1756-8927 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03611918v1 |
| source | MEDLINE; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; PubMed Central |
| subjects | Anti-Bacterial Agents - chemistry Anti-Bacterial Agents - pharmacology antibiotics atypical mycobacteria Chemical Sciences Chemistry, Medicinal Heterocyclic Compounds - chemistry Heterocyclic Compounds - pharmacology heterocylic compounds Life Sciences Life Sciences & Biomedicine mechanisms of action Microbial Sensitivity Tests Molecular Structure Mycobacterium Infections, Nontuberculous - drug therapy Mycobacterium Infections, Nontuberculous - microbiology nontuberculous mycobacteria Nontuberculous Mycobacteria - drug effects Pharmacology & Pharmacy Science & Technology Structure-Activity Relationship structure–activity relationships |
| title | A review of current and promising nontuberculous mycobacteria antibiotics |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T08%3A15%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20review%20of%20current%20and%20promising%20nontuberculous%20mycobacteria%20antibiotics&rft.jtitle=Future%20medicinal%20chemistry&rft.au=Cantelli,%20Christophe%20R.&rft.date=2021-08-01&rft.volume=13&rft.issue=16&rft.spage=1367&rft.epage=1395&rft.pages=1367-1395&rft.issn=1756-8919&rft.eissn=1756-8927&rft_id=info:doi/10.4155/fmc-2021-0048&rft_dat=%3Cproquest_hal_p%3E2544879470%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2544879470&rft_id=info:pmid/34165325&rfr_iscdi=true |